Leveraging Vγ9Vδ2 T cells against prostate cancer through a VHH-based PSMA-Vδ2 bispecific T cell engager.
King LA, Veth M, Iglesias-Guimarais V, Blijdorp I, Kloosterman J, Vis AN, Roovers RC, Hulsik DL, Riedl T, Adang AEP, Parren PWHI, van Helden PM, de Gruijl TD, van der Vliet HJ.
King LA, et al.
iScience. 2024 Oct 30;27(12):111289. doi: 10.1016/j.isci.2024.111289. eCollection 2024 Dec 20.
iScience. 2024.
PMID: 39628574
Free PMC article.